Oramed Pharmaceuticals Inc. (ORMP) Financial Statements (2024 and earlier)
Company Profile
| Business Address |
1185 AVENUE OF THE AMERICAS, 3RD FLOOR NEW YORK, NY 10036 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)Annual | Quarterly
| 3/31/2024 Q1 | 12/31/2023 Q4 | 9/30/2023 Q3 | 6/30/2023 Q2 | 3/31/2023 Q1 | 12/31/2022 Q4 | 9/30/2022 Q3 | |||
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Current Assets | |||||||||
| Cash, cash equivalents, and short-term investments | 66,768 | 5,517 | 7,710 | 26,371 | 44,207 | 38,430 | |||
| Cash and cash equivalents | 9,055 | 5,468 | 6,767 | 24,104 | 40,464 | 33,196 | |||
| Short-term investments | 57,713 | 49 | 943 | 2,267 | 3,743 | 5,234 | |||
| Deposits current assets | 95,279 | 120,158 | 142,491 | 127,363 | 111,513 | 121,119 | |||
| Other undisclosed current assets | 537 | 50,030 | 769 | 1,423 | 1,389 | 623 | |||
| Total current assets: | 162,584 | 175,705 | 150,970 | 155,157 | 157,109 | 160,172 | |||
| Noncurrent Assets | |||||||||
| Operating lease, right-of-use asset | 694 | 768 | 842 | 915 | 987 | 1,005 | |||
| Property, plant and equipment | 873 | 923 | 945 | 977 | 815 | 535 | |||
| Long-term investments and receivables | 37,160 | 31 | 3,524 | 2,700 | 2,700 | 2,700 | |||
| Long-term investments | 37,160 | 31 | 3,524 | 2,700 | 2,700 | 2,700 | |||
| Deposits noncurrent assets | 7 | 6 | 7 | ||||||
| Other undisclosed noncurrent assets | 19,233 | 53,460 | 26 | 31 | 31 | 25 | |||
| Total noncurrent assets: | 57,967 | 55,188 | 5,344 | 4,623 | 4,533 | 4,265 | |||
| TOTAL ASSETS: | 220,551 | 230,893 | 156,314 | 159,780 | 161,642 | 164,437 | |||
| LIABILITIES AND EQUITY | |||||||||
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts payable and accrued liabilities, including: | 1,609 | 2,561 | 828 | 4,055 | 4,158 | 4,205 | |||
| Accrued liabilities | 453 | 5 | |||||||
| Other undisclosed accounts payable and accrued liabilities | 1,156 | 2,561 | 828 | 4,055 | 4,153 | 4,205 | |||
| Deferred revenue | 2,000 | ||||||||
| Debt | 51,338 | 75,363 | 3 | 1 | |||||
| Other liabilities | 59 | 59 | 96 | 96 | 133 | ||||
| Due to related parties | ✕ | ✕ | ✕ | ✕ | ✕ | 1 | 70 | ||
| Other undisclosed current liabilities | 208 | 192 | 140 | 820 | 1,587 | 117 | |||
| Total current liabilities: | 53,214 | 78,175 | 1,067 | 4,972 | 5,746 | 6,525 | |||
| Noncurrent Liabilities | |||||||||
| Long-term debt and lease obligation: | 672 | ||||||||
| Liabilities, other than long-term debt | 4,342 | 4,389 | 4,488 | 4,564 | 4,647 | 4,000 | |||
| Deferred revenue | 4,000 | 4,000 | 4,000 | 4,000 | 4,000 | 4,000 | |||
| Operating lease, liability | 342 | 389 | 488 | 564 | 647 | 672 | |||
| Other undisclosed noncurrent liabilities | 102 | 99 | 104 | 96 | 93 | 93 | |||
| Total noncurrent liabilities: | 4,444 | 4,488 | 4,592 | 4,660 | 4,740 | 4,765 | |||
| Total liabilities: | 57,658 | 82,663 | 5,659 | 9,632 | 10,486 | 11,290 | |||
| Equity | |||||||||
| Equity, attributable to parent | 163,821 | 149,132 | 151,546 | 150,970 | 151,812 | 153,808 | |||
| Common stock | 485 | 484 | 484 | 481 | 476 | 470 | |||
| Additional paid in capital | 320,892 | 319,540 | 318,732 | 316,965 | 314,417 | 307,876 | |||
| Accumulated deficit | (157,556) | (170,892) | (167,670) | (166,476) | (163,081) | (154,538) | |||
| Equity, attributable to noncontrolling interest | (928) | (902) | (891) | (822) | (656) | (661) | |||
| Total equity: | 162,893 | 148,230 | 150,655 | 150,148 | 151,156 | 153,147 | |||
| TOTAL LIABILITIES AND EQUITY: | 220,551 | 230,893 | 156,314 | 159,780 | 161,642 | 164,437 | |||
Income Statement (P&L) ($ in thousands)Annual | Quarterly
| 3/31/2024 Q1 | 12/31/2023 Q4 | 9/30/2023 Q3 | 6/30/2023 Q2 | 3/31/2023 Q1 | 12/31/2022 Q4 | 9/30/2022 Q3 | ||
|---|---|---|---|---|---|---|---|---|
| Revenues | 674 | 666 | 681 | 682 | ||||
| Revenues, excluding interest and dividends | ||||||||
| Gross profit: | 674 | 666 | 681 | 682 | ||||
| Operating expenses | (4,164) | (2,893) | (4,465) | (5,874) | (43,301) | (8,871) | ||
| Other undisclosed operating income (loss) | 287 | 32,880 | ||||||
| Operating loss: | (3,877) | (2,893) | (3,791) | (5,208) | (9,740) | (8,189) | ||
| Nonoperating income | 18,384 | 435 | 1,550 | |||||
| Gain, foreign currency transaction, before tax | 1,550 | |||||||
| Interest and debt expense | (1,211) | (826) | ||||||
| Income (loss) from continuing operations before equity method investments, income taxes: | 13,296 | (3,284) | (3,791) | (5,208) | (8,190) | (8,189) | ||
| Other undisclosed income (loss) from continuing operations before income taxes | (1,930) | 1,036 | ||||||
| Income (loss) from continuing operations before income taxes: | 13,296 | (3,284) | (3,791) | (5,208) | (10,120) | (7,153) | ||
| Income tax expense | (100) | |||||||
| Other undisclosed income from continuing operations | 39,248 | |||||||
| Income (loss) from continuing operations: | 13,296 | (3,284) | (3,791) | (5,208) | 29,128 | (7,253) | ||
| Loss before gain (loss) on sale of properties: | ✕ | ✕ | ✕ | ✕ | ✕ | ✕ | (7,253) | |
| Other undisclosed net income (loss) | 2,478 | 1,597 | (37,864) | |||||
| Net income (loss): | 13,296 | (3,284) | (1,313) | (3,611) | (8,736) | (7,253) | ||
| Net income attributable to noncontrolling interest | 40 | 62 | 119 | 216 | 193 | 193 | ||
| Net income (loss) available to common stockholders, diluted: | 13,336 | (3,222) | (1,194) | (3,395) | (8,543) | (7,060) | ||
Comprehensive Income ($ in thousands)Annual | Quarterly
| 3/31/2024 Q1 | 12/31/2023 Q4 | 9/30/2023 Q3 | 6/30/2023 Q2 | 3/31/2023 Q1 | 12/31/2022 Q4 | 9/30/2022 Q3 | ||
|---|---|---|---|---|---|---|---|---|
| Net income (loss): | 13,296 | (3,284) | (1,313) | (3,611) | (8,736) | (7,253) | ||
| Comprehensive income (loss): | 13,296 | (3,284) | (1,313) | (3,611) | (8,736) | (7,253) | ||
| Comprehensive income, net of tax, attributable to noncontrolling interest | 40 | 62 | 119 | 216 | 193 | |||
| Other undisclosed comprehensive loss, net of tax, attributable to parent | (1,010) | |||||||
| Comprehensive income (loss), net of tax, attributable to parent: | 13,336 | (3,222) | (1,194) | (3,395) | (9,746) | (7,060) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.